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A B S T R A C T
Community-acquired infections, including respiratory tract infections (RTIs) and urinary tract infections
(UTIs), represent a major burden for most healthcare systems, partially due to ineffective or
inappropriate antibiotic treatment leading to clinical failure, which often requires alternative antibiotics
for cure. Appropriate antimicrobial use not only maximises clinical success in the treatment of
community-acquired infections, but also minimises unintended consequences such as resistance
development or collateral damage. This article outlines a range of antibiotic stewardship strategies and
other preventative approaches that support the management of community-acquired infections, based
on existing antibiotic use for community-acquired infections and the current resistance patterns among
common RTI and UTI pathogens.
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Community-acquired infections, including respiratory tract infec-
tions (RTIs) and urinary tract infections (UTIs), represent a major
burden for every healthcare system, particularly when ineffective or
inappropriate antibiotic treatment leads to clinical failure. Inappro-
priate use of antibiotics increases the risk of resistance development
and it persists as a key issue in the management of these conditions
unless effective antibiotic stewardship programmes are implemented.
Due to indiscriminate use of antibiotics, the prevalence of drug-
resistant pathogens [e.g. penicillin-resistant Streptococcus pneumo-
niae, macrolide-resistant  Mycoplasma pneumoniae and extended-
spectrumb-lactamase(ESBL)-producingEscherichia coli] implicated in
community-acquired infections has reached a critical level worldwide.
However, low antibiotic consumption is possible without harming
public health and also reduces the risk for microbial resistance.
1.1. Antibiotic consumption correlates with antibiotic resistance
There is a clear positive association between antibiotic consump-
tion and antibiotic resistance at the national or global level [1]. It has
been demonstrated that in countries where antibiotic prescription
rates are very high, the level of antibiotic resistance also reached an
unacceptable level making most drugs ineffective. For example, in
Europe antibiotic prescription/consumption is highest in southern
countries and lowest in the north [1], but even larger volumes of
antibiotic consumption are reported for the USA [2]. Furthermore, in
some developing low-income countries such as Vietnam, patients
with a respiratory infection may be treated with cheap generic
antibiotics, as healthcare costs represent a huge societal burden [3].
Although clinical practice guidelines provide clear recommendations
on antibiotic use both for hospitalised patients and outpatients, these
are often not followed by physicians [4,5]. This may be due to a fear of
surgical-site infection, which prompts inappropriate use of antibiotic
prophylaxis [3], or diagnosis in ambulatory services may be
incorrect (i.e. misdiagnosing viral infection as having a bacterial
aetiology) [5–7]. In addition, diagnostic tools are often inadequate
in primary care, with bacteriological information frequently
lacking for respiratory specimens. Antibiotic use in the commu-
nity for recurrent UTIs is ca. 10–15% of the total volume of
antibiotic prescriptions [8], most typically prescribed by general
practitioners. In principle, treatment of patients with recurrent
UTI is based on their clinical symptoms, although urine analysis
would conﬁrm the presence of a bacterial pathogen. The
increasing prevalence of resistant bacteria causing UTIs is directly
related to inappropriate antibiotic prescribing even though
alternative strategies may be available [4,9]. Therefore, inappro-
priate antibiotic use is multifactorial both in hospital and
community settings, leading to widespread antibiotic resistance
[10–12].
Antibiotic resistance is now recognised as a global problem, with
only a few novel antibiotics in the pipeline [13,14]. More
importantly, the number of approved new antibiotics has decreased
dramatically in the last decade [14] and it is therefore vital to
preserve the currently available antibiotics for future generations.
Resistance to antibiotics routinely used for community-acquiredinfections is extremely high in some regions and it is essential that
clinicians are aware of local resistance patterns when treating their
patients empirically.
1.2. Antibiotic resistance in respiratory pathogens
The most prevalent respiratory pathogens (with some resis-
tance threat) are S. pneumoniae, Haemophilus inﬂuenzae, atypical M.
pneumoniae and certain Gram-negative pathogens such as
Moraxella catarrhalis, E. coli, Pseudomonas aeruginosa (which is
intrinsically drug-resistant) and Acinetobacter baumannii [multi-
drug-resistant (MDR)].
1.2.1. S. pneumoniae
S. pneumoniae has the highest prevalence both in lower and upper
RTIs, including community-acquired pneumonia (CAP), acute
exacerbations of chronic obstructive pulmonary disease (COPD)
and acute bacterial rhinosinusitis (ABRS), as well as in acute otitis
media in paediatric patients. Changes in the penicillin breakpoints in
2008 for S. pneumoniae [15,16] allowed clinicians to increase the use
of penicillin to treat penicillin-susceptible non-meningitis pneumo-
coccal infections, instead of using broader-spectrum antimicrobials.
Its use is encouraged to prevent the spread of antimicrobial-resistant
S. pneumoniae as well as methicillin-resistant Staphylococcus aureus
(MRSA) and Clostridium difﬁcile, which can result from the use of
broader-spectrum antimicrobials [17].
Resistance among S. pneumoniae strains to macrolide anti-
biotics shows an increasing prevalence worldwide, being particu-
larly high in Asia and varying among countries in Europe [18–20].
Fluoroquinolone (FQ) resistance at present is a less signiﬁcant
problem in the treatment of RTIs caused by S. pneumoniae [21–23],
but resistant strains may emerge in immunocompromised patients
[24], patients with structural lung disease and those with previous
antibiotic exposure [25].
In many countries of the world, chloramphenicol, trimetho-
prim/sulfamethoxazole (SXT) and tetracyclines have reached such
a level of resistance that they are no longer a good option for
empirical therapy in RTIs of pneumococcal aetiology.
1.2.2. H. inﬂuenzae
b-Lactamase production is the primary mechanism of resistance
among H. inﬂuenzae and is a well-known predictor of treatment
failure in community-acquired RTIs. Between 2004 and 2005, the
mean prevalence of b-lactamase-producing strains in Europe was
reported to be 7.6% (range 0.7–17.6%) [26]. In addition, H. inﬂuenzae
isolates carrying amino acid substitutions in the ftsI gene [encoding
penicillin-binding protein 3 (PBP3)] are phenotypically recognised
as b-lactamase-negative ampicillin-resistant (BLNAR), which leads
to loss of susceptibility to aminopenicillins and some cephalospor-
ins. Azithromycin is the most active macrolide against H. inﬂuenzae,
with a minimum inhibitory concentration (MIC) four- to eightfold
lower than erythromycin (azithromycin MICs, <0.25–4 mg/L).
However, the existence of efﬂux pumps leads to loss of susceptibility
to macrolides in >98% of H. inﬂuenzae strains [27]. Some of these
strains are hyper-resistant (1.3%; azithromycin MICs >4 mg/L) due
to ribosomal mutations [27]. Occasional hyper-susceptible strains
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underlying mechanism of resistance and appear to be the only truly
macrolide-susceptible variants of H. inﬂuenzae [27].
1.2.3. M. catarrhalis
The susceptibility of M. catarrhalis has changed little since
1999. Of note, despite almost universal b-lactamase prevalence,
resistance to other antibacterial agents has not developed in
M. catarrhalis. Clinicians should assume that all isolates of
M. catarrhalis are resistant to amoxicillin, ampicillin, piperacillin
and penicillin.
1.2.4. M. pneumoniae
M. pneumoniae is inhibited by tetracyclines, macrolides,
ketolides and FQs, with little variation in MICs among clinical
isolates. Macrolide-resistant strains are on the rise; whilst they
remain rare in Europe, a high prevalence of resistance has recently
been reported from East Asia [28].
1.3. Antibiotic resistance in urinary tract infection pathogens
The most prevalent bacteria in UTIs are E. coli (ca. 50–80%)
followed by Klebsiella pneumoniae and Proteus mirabilis [9,29–31].
Appropriate antibiotic prescribing for UTIs is essential, since
bacteraemia originating from a UTI is frequent (incidence rate of
55.3 per 100 000 person-years) [32]. The overall rate of communi-
ty-onset E. coli bacteraemia in seniors (65 years of age) has been
found to be as high as 150 cases/100 000 person-years, which was
approximately three times higher than the rate of pneumococcal
bacteraemia [33].
1.3.1. Enterobacteriaceae
Resistance to b-lactam antibiotics in E. coli is increasing [34]. In
a recent survey of antibiotic susceptibility in community urinary
isolates from a metropolitan area, ampicillin resistance was
observed in 53% of E. coli and 28% of P. mirabilis isolates. In
addition, 34% of E. coli and P. mirabilis isolates were found to be
non-susceptible to trimethoprim compared with 20% of Klebsiella
spp., whilst nitrofurantoin resistance was observed in 3% of E. coli
and 15% of Klebsiella spp. [35]. SXT resistance, which is plasmid-
mediated, has been commonly recognised [10,31,36–39]; there-
fore, this combination is no longer considered as ﬁrst-line therapy
in the management of UTIs. FQ resistance in UTI pathogens has also
increased globally, with the SMART study reporting resistance
rates between 6% and 75% in Gram-negative urinary pathogens
isolated from hospitalised patients [40].
The occurrence of ESBLs in the recent survey was low (6%), as
was non-susceptibility to carbapenems, cefepime and tigecycline
(<2%) [35]. Further monitoring of this level of resistance is required
and additional clinical studies would highlight the impact on the
outcome of current empirical prescribing decisions.
The rate of ESBL-producing strains in European countries or in
the USA varies between 0% and 40% or higher, with the prevalence
of resistant bacteria increasing over the last decade [10,31,37–39].
Acquisition of MDR ESBL-producing Enterobacteriaceae among the
faecal ﬂora during international travel is common. When the
geographical areas were speciﬁed, India, Asia and Africa north of
the equator were found to be the areas associated with high risk
[41]. As ESBLs become more prevalent, broad-spectrum agents
such as carbapenems are being used increasingly as empirical
treatment for severe UTIs. However, recently E. coli producing
carbapenemase [New Delhi metallo-b-lactamase (NDM)] have
been reported at an alarming rate [42].
With the escalating resistance to cephalosporins and FQs,
fosfomycin and nitrofurantoin are likely to be used increasingly
against ESBL-producing E. coli. Resistance to these antibiotics islow, although increased fosfomycin resistance in ESBL-producing
E. coli has been reported [31,38,43]. In contrast to the increasing
resistance of E. coli to other b-lactam antibiotics, resistance to
pivmecillinam remains low [38]. However, it should also be noted
that whilst pivmecillinam is recommended in current treatment
guidelines for UTIs, it is not available in many countries.
2. The role of antibiotic stewardship in limiting antibiotic
resistance
Against a background of escalating antibiotic resistance, it is
important to preserve antibiotic efﬁcacy for patients (adults and
children) who will beneﬁt most from their appropriate use [44].
For many years, development of antibiotic resistance was
associated with hospitals owing to lack of infection or hygiene
control. However, the threat of escalating antibiotic resistance is
now also recognised in community settings, particularly for those
who are the most vulnerable to infections owing to lower degrees
of immunity (e.g. children and the elderly) [45–47], yet the risk
remains underrated. There is therefore a high medical and societal
need for antibiotic stewardship in community settings. In most
countries, antibiotic stewardship programmes in hospitals are at
an early stage and they are nearly non-existent in the community,
including long-term healthcare facilities and primary care settings
(e.g. ambulatory services, general practice).
The dual purpose of antibiotic stewardship is to maximise the
clinical success of antibiotics used to treat community-acquired
infections and to minimise the unintended consequences of their
use, such as resistance development or collateral damage [48].
Initial antibiotic therapy is empirical and should be based on the
most likely diagnosis and patient characteristics with a view to de-
escalation to the most appropriate antibiotic once the pathogen is
known; this reduces the risk of poor clinical outcome and
resistance development.
2.1. Challenges in antibiotic stewardship in hospital and community
settings
Overuse or inappropriate use of currently available antibiotics
in clinical practice has led to the development of highly resistant
MRSA, P. aeruginosa, A. baumannii, enterococci, ESBL-producing
E. coli, and MDR or extensively drug-resistant (XDR) Mycobacterium
tuberculosis in the hospital environment and in some community
settings [30,45].
In hospital settings, many resources are available for co-
ordination of an antibiotic stewardship programme, including
physicians, pharmacists, nurses, infectious diseases specialists and
microbiology laboratories for identiﬁcation of bacteria [49,50].
However, lack of availability of similar resources in community
settings makes implementation of such programmes more
problematic.
The management of hospitalised patients differs vitally from
that of outpatients in the option to switch rapidly to a narrow-
spectrum antibiotic drug when exact information is available
about the pathogen. This de-escalation increases the likelihood of
clinical success and also minimises the risk of resistance
development. There is some evidence suggesting that antibiotic
stewardship has had a positive impact on various outcome
parameters, reducing mortality rate [51,52], recurrent infection
rate [53], length of hospital stay [54,55], duration of therapy [54]
and superinfection with MDR bacteria [56], and it can also
indirectly reduce the cost of treatment [57,58].
Since delays in initiating therapy result in a poorer outcome in
severely ill patients [59], initial empirical therapy is often broad
spectrum considering local antibiotic resistance patterns. Obtaining
a culture result early in therapy and assessing the patient’s response
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[53] or to stop the antibiotic. Of note, microbiological analysis of
various biospecimens (i.e. sputum or urine) to determine the
exact pathogen and its susceptibility in outpatient settings is
impractical; therefore, clinical symptoms and signs are key
determinants of antibiotic prescription. Decreasing exposure to
antibiotics also reduces the likelihood of resistance development
and collateral damage such as C. difﬁcile infection [60,61].
Consequently, in hospitals shortened courses of antibiotics should
be used whenever possible [62–64]. Conversely, controlling the
duration of antibiotic therapy in the community is virtually
impossible. Furthermore, the efﬁcacy of an antibiotic may depend
on its therapeutic level, which can be monitored in hospitals and
adjusted, if required; however, this is not feasible in outpatient
settings. As a result, optimal dosing of outpatients in the
community is unrealistic due to the lack of exact bacteriological
results and therapeutic drug concentrations.
2.2. Collateral damage and collateral beneﬁt
Collateral damage of antibiotic therapy and the associated
development of MDR bacteria (i.e. C. difﬁcile or P. aeruginosa
infection) is a well recognised phenomenon that is particularly
associated with the use of FQs and cephalosporins [65,66]. Certain
antibiotics such as nitrofurantoin and pivmecillinam are associat-
ed with a reduced risk of collateral damage owing to their lower
potential for resistance selection. These antibiotics should have
preference in UTIs [67].
Collateral beneﬁts, however, may be recognised in hospitals
after unnecessary antibiotic therapy is discontinued or replaced
[68], reducing antibiotic pressure on certain bacteria. For example,
increased use of ertapenem vs. imipenem has been reported to
reduce the development of imipenem-resistant P. aeruginosa
owing to the lower antipseudomonal activity of ertapenem
[68,69]. Restricting third-generation cephalosporin use has also
been shown to reduce the incidence of C. difﬁcile infection [70,71].
However, implementation of such practices is more difﬁcult in the
community setting owing to the lack of culture data, patient
follow-up and information on adherence.
2.3. Implementing an antibiotic stewardship programme
There are many factors that need to be taken into consideration
when antibiotic stewardship programmes are initiated, with
support provided by authorities, payers, hospitals, primary care
facilities and public. Minimising the risk of hospitalisation as well
as reducing healthcare costs and antimicrobial resistance requires
a range of interventions and preventative strategies. Antibiotic
stewardship for RTIs includes shortening the treatment duration
and de-escalation of antibiotics in pneumonia patients, immunisa-
tion and vaccination programmes for COPD patients and those at
high risk of unfavourable outcome, and correctly diagnosing
sinusitis patients who would beneﬁt from antibiotic therapy.
Preventative strategies are outlined in the latest European
Respiratory Society (ERS) and American Thoracic Society (ATS)/
Infectious Diseases Society of America (IDSA) guidelines and take
into consideration the health status of patients suffering from, or
with risk factors for, a pulmonary or respiratory disease [6,72,73].
Vaccination strategies for bacterial infections such as meningitis
(which has symptoms similar to respiratory infections) and
pneumonia were also demonstrated to have a signiﬁcant impact
on the prevalence of these diseases in the community setting
[74,75]. In particular, vaccination against pneumococcus in
children has signiﬁcantly reduced infection rates, hospitalisation
rates due to RTIs, healthcare costs and deaths among the elderly in
the community [72,76,77]. Elderly patients who are hospitalisedwith a RTI should also be vaccinated against pneumococcus or
inﬂuenza when they are discharged from hospital.
Similarly, preventative approaches are described in the current
guidelines for the management of UTIs, although immunisation
strategies are not yet developed for such infections as no vaccine
exists currently. However, positive outcomes have been observed
using bacterial lysates to promote immunostimulation as a
method to prevent infection [78], or bacterial interference to
suppress pathogenic bacteria in an attempt to reduce antibiotic use
[79].
Implementation of preventative strategies remains poor,
underlying the need of improved education of clinicians, primary
care physicians, nurses, prescribers and the public. Recently, a joint
statement by the IDSA, Pediatric Infectious Diseases Society (PIDS)
and Society for Healthcare Epidemiology of America (SHEA) has
recommended that antimicrobial stewardship programmes should
be mandatory in hospitals, monitored via electronic health
records and should form part of a formal education and research
programme. No such guideline or policy statement exists for the
implementation and management of a stewardship programme
in the community setting, although certain initiatives have been
effective in altering antibiotic prescription behaviour in primary
care [80]. Pulcini and Gyssens have also advised that broader
education on antibiotic stewardship practices should be
enforced by governments, ministries and academia, not only
targeting healthcare professionals and patients, but also trainee
doctors, parents and children [81]. Pragmatic monitoring and
prudent use of antimicrobials have favourable effects on
resistance levels and help preserve the efﬁcacy of antimicrobials
[82].
Implementation of antibiotic stewardship in the community
may be complicated by the variety of settings where patients
could be treated with antibiotics. On one hand, management of
RTIs and UTIs takes place in primary care (such as ambulatory
services, emergency departments and general practice) or in long-
term care facilities. It is believed that long-term care facilities are
becoming reservoirs of MDR pathogens owing to close contact
among residents who might have received previous courses of
antibiotics or intravenous outpatient antibiotics for a community-
acquired infection. Residents may also have been chronically
infected as a result of a chronic respiratory illnesses (e.g. COPD or
bronchiectasis) or have co-morbidities (e.g. immunosuppression,
cancer).
Under such a variety of patient settings, implementation of
strategies to reduce antibiotic pressure is rather difﬁcult. This has
been highlighted by a recent analysis of the antibiotic prescription
behaviour of physicians in 45 Dutch primary care practices
between 2007 and 2010, which revealed that antibiotics were
most often used incorrectly for upper RTIs [7]. Such monitoring
at a national level can help unravel the reasons for increased
antibiotic resistance and allow authorities to intervene. For
example, it has recently been reported by Jump et al. that
antibiotic use in long-term care facilities was reduced by 25–30%
after rigorous consultation services were implemented, and this
alleviated the antibiotic resistance level [82]. In 2011, the
Scottish Government published its strategies to address the
increasing problem of antibiotic resistance, which led to some
early successes [83]. For example, the recommendations of the
Scottish Antimicrobial Prescribing Group helped optimise
antibiotic prescription in hospitals and primary care, developed
training materials for healthcare professionals, qualitatively
improved the management of CAP and reduced the C. difﬁcile
infection rate [83]. A similar stringent framework for antibiotic
prescription was outlined in 2008 by the government of
Singapore after recognising the lack of control over antibiotic
use in public sector hospitals [84].
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antibiotic stewardship strategies
Community-acquired upper and lower RTIs among adults are
the most common reasons for visiting primary care physicians.
Prevention of RTIs is important since recurrent infections impact
considerably on patients’ quality of life and outcome, in some cases
leading to severe dyspnoea requiring hospitalisation and mechan-
ical ventilation, or even death. More than 50% of children seeking
medical treatment in industrialised countries are suffering from a
RTI compelling both children and their parents to alter their daily
routine. Many of these infections are recurrent (due to prior
ineffective antibiotic courses) and include acute otitis media,
tonsillitis, sinusitis, bronchiolitis, pneumonia and COPD exacer-
bations.
3.1. Role of non-pharmacological and pharmacological interventions
in reducing respiratory infections
As mentioned above, preventative strategies are outlined in
clinical practice guidelines to minimise the need for antibiotics for
RTIs [6,72,73]. In COPD patients, ca. 50% of acute exacerbations
have bacterial aetiology [85], whilst 25% have a viral origin
predisposing to secondary bacterial infection, prolonging the
duration of illness. In the management of stable COPD, certain
continuous non-pharmacological strategies such as smoking
cessation, pulmonary rehabilitation, supplemental oxygen, patient
education and self-management are recommended to improve
quality of life [72,86]. Pharmacological interventions may also
reduce the frequency of exacerbation episodes of chronic
bronchitis or COPD and include inhaled long-acting b2 receptor
agonists, long-acting anticholinergics, inhaled corticosteroids and
systemic antibiotics for complicated patients.
The role of bacteria in acute sinusitis is not fully understood,
with symptoms overlapping with those occurring in viral common
cold [6], potentially leading to inappropriate antibiotic use. Use of
antibiotics should be preserved for those ABRS patients who have
purulent nasal discharge and more severe disease with high fever
[6]. In chronic rhinosinusitis patients, prophylactic antibiotics are
given only to immunosuppressed patients, and the recurrence of
infections is prevented with nasal corticosteroids in immunocom-
petent patients [6].
3.2. Vaccination
Vaccination is recommended for immunocompetent people
who are at higher risk of an unfavourable outcome from inﬂuenza
infection or pneumococcal disease [72], although such policies do
not prevent further respiratory infections completely.
Inﬂuenza vaccinations are also currently recommended as part of
the management of people with COPD, based largely on evidence
from observational studies since few randomised controlled trials
(RCTs) have been reported. It has been reported that inactivated
inﬂuenza vaccine reduces exacerbations in COPD patients [87]. There
is a mild increase in transient local adverse effects with vaccination,
but no evidence of an increase in early exacerbations [88].
Data on pneumococcal vaccination are limited although
available studies suggest a beneﬁcial effect in COPD and its use
is recommended for COPD patients aged 65 years and for younger
patients with signiﬁcant co-morbidity [72,74,86,88]. In addition,
pneumococcal vaccination has been shown to reduce the incidence
of CAP in COPD patients aged <65 years and in those with severe
COPD with an FEV1 (forced expiratory volume in 1 s) <40%
predicted [88]. In CAP, S. pneumoniae is the most prevalent
pathogen and some aggressive highly virulent forms may causeinvasive disease or meningitis. Studies conﬁrmed the positive
impact of vaccination on the rate of pneumococcal pneumonia and
invasive disease, therefore this vaccination is recommended in all
who are elderly or at higher risk of pneumococcal disease [72,86].
3.3. Immunostimulation
Immunostimulation with bacterial lysates may also have a role
in preventing bacterial respiratory infections [89,90]. The correla-
tion between recurrent RTIs and immunological deﬁciency
suggests a rationale for development of immunostimulating
preventive treatments for such patients. In contrast to pneumo-
coccal vaccines, bacterial lysates are prepared from a wide range of
pathogenic bacteria and are composed of the antigens of the most
commonly occurring upper and lower respiratory tract pathogens.
OM-85, a chemical bacterial lysate, contains antigens from eight
different prevalent pathogenic bacteria implicated in RTIs. Data
suggest that, after oral administration, OM-85 strengthens the
basal activity of the innate immune system through activation of
macrophages and dendritic cells and stimulates adaptive immu-
nity via antibody production; thus, the immune system could
maintain a strengthened and modulated defence [91,92]. Substan-
tial reductions in the frequency of RTIs in children have been
demonstrated with OM-85 with good tolerability [93–96] and with
a signiﬁcant decrease in antibiotic consumption [94,97].
Immunostimulation with OM-85 has been shown to alleviate
symptoms and recurrence of sinusitis in adults [98], allowing
consideration as an adjunct therapy in adults with chronic
rhinosinusitis without nasal polyps [6]. In COPD patients, OM-85
signiﬁcantly reduced the frequency of acute exacerbations [99],
chronic bronchitis [100], length of hospitalisation [101] and the
requirement for antibiotic treatment [102] and also improved
dyspnoea [101,102], sputum and cough scores [102]. Although these
ﬁndings are promising, conﬁrmation from larger clinical trials are
required for bacterial lysates to be recommended by respiratory
guidelines [72,73,86].
4. Effective strategies in reducing urinary tract infection rates
and preventing recurrent infections
Community-acquired UTIs are very common in adult females
and elderly males. The most frequent forms are cystitis, prostatitis
and pyelonephritis, with severe symptoms impairing the quality of
life (e.g. rapid-onset dysuria, urinary frequency, urinary urgency
and even unbearable pain). It is estimated that ca. 40% of adult
women and 12% of men will experience at least one symptomatic
episode of uncomplicated UTI per year and in 25% of these women
the infection will recur [103]. Of note, a considerable number of
patients are admitted to hospital every year due to UTIs (100 000
cases per year in the USA), with 40% of all hospital-acquired
infections being UTIs (mostly catheter-associated).
Two main levels of severity can be described regarding UTIs,
uncomplicated and complicated, the prevalence of which is not
well known. Uncomplicated UTI requires mostly empirical
antibiotic therapy to heal without sequelae, whilst complicated
UTI needs more complex management and combination therapy.
UTIs can also develop into bacteraemia, sepsis and septic shock if
the pathogen is invasive in nature, requiring complex management
and life-supporting care.
The increasing rate of colonisation of MDR E. coli in the intestinal
ﬂora has consequently been demonstrated as a risk factor for febrile
UTI and sepsis after prostate biopsy, which is the most common
invasive urological procedure with many thousands being per-
formed in Europe annually. Major efforts are now undertaken in the
urological community to reduce the risk for post-biopsy fever by
J. Garau et al. / Journal of Global Antimicrobial Resistance 2 (2014) 245–253250emphasising the need for antibiotic stewardship programmes and
appropriate pre-diagnostic and therapeutic procedures [104].
The latest European Association of Urology (EAU) guidelines
provide detailed recommendations for antibiotic treatment for
various UTIs [9], with prevention being advocated for uncompli-
cated UTI in otherwise healthy women, including lifestyle changes
(e.g. hygiene improvement, adequate ﬂuid consumption), non-
antibiotic prophylaxis and continuous antibiotic prophylaxis when
other preventative strategies are unsuccessful.
4.1. Bacterial interference as a strategy to reduce antibiotic use
Bacterial interference (displacement of one bacterial species for
another in the same tissue to become the main coloniser) may be
an effective therapy for uncomplicated UTI. As asymptomatic
bacteriuria (ABU) has been proven to protect against symptomatic
superinfections [105,106], RCTs have shown that deliberate
colonisation of the lower urinary tract with an E. coli ABU isolate
can be used as an alternative treatment option [107,108]. Delivery
of lactobacilli, for example, through local (vaginal) application has
been shown to result both in clinical improvement and reduction
in recurrent UTI in a randomised placebo-controlled study [109]. In
addition, oestrogen therapy in post-menopausal women increases
the number of lactobacilli in the normal ﬂora, which indirectly may
provide beneﬁt against recurrent infections [110].
4.2. Complementary therapies in urinary tract infections
Complementary therapies for UTIs include the consumption of
cranberry juice or cranberry extract in order to inhibit bacterial
adhesion on uroepithelial cells, although data on the effectiveness
of this strategy remain controversial [9]. In vitro data have shown
that cranberries contain a tannin called proanthocyanidin, which
inhibits P-ﬁmbrial adhesion of E. coli to uroepithelial cells.
Although several clinical studies have been conducted, the results
are contradictory and, as the dosage has not been standardised or
clearly deﬁned, it is difﬁcult to draw a deﬁnitive conclusion [111].
4.3. Immunostimulation with bacterial lysate
Bacterial lysate immunostimulants have been investigated as a
potential therapeutic strategy for UTI [112]. One such agent, OM-
89, is an oral E. coli bacterial lysate that contains antigens from 18
different E. coli strains. In pre-clinical models, OM-89 stimulates
both the innate immune system and the adaptive immune
responses. In clinical studies, OM-89 signiﬁcantly reduced the
number of episodes of UTI by 36% compared with placebo, with a
higher proportion of OM-89-treated women remaining free from
recurrent cystitis (65% vs. 46% in the placebo group; P < 0.001), and
the remaining 35% of women receiving OM-89 also had fewer
infections than placebo-treated women [113]. In addition,
stimulation of the immune system with OM-89 signiﬁcantly
reduced the need for antibiotics in UTIs by 50% compared with
placebo [114] and reduced the number of antibiotic (FQs and b-
lactams) prescriptions by 13% (P = 0.005) over a 12-month period
[115], with good tolerability also being demonstrated in a range of
patients [116–118]. As a result, the latest EAU guidelines
recommend OM-89 for non-antimicrobial prophylaxis to prevent
recurrent infections in otherwise healthy women suffering from
recurrent uncomplicated UTI [9].
5. Conclusions and summary
Antibiotic resistance development remains a critical issue for
the management of infections both in community and hospital
settings. In a hospital environment, antibiotic stewardshipprogrammes involving cross-functional teams have demonstrated
a positive impact on encouraging appropriate use of antibiotics.
However, similar programmes are difﬁcult to implement in the
community. Consequently, to improve clinical outcomes in commu-
nity-acquired infections and to reduce resistance development
pressure, preventative strategies should be encouraged more
vigorously along with continuing education of patients and
healthcare professionals. Preventative approaches such as vaccina-
tion and immunostimulation may become fundamental in ensuring a
decline of community-acquired infections and indirectly may lead to
more optimised antibiotic use in the community.
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